Mezzion Pharma Co.Ltd (140410) - Total Assets
Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) holds total assets worth ₩98.92 Billion KRW (≈ $67.04 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Mezzion Pharma Co.Ltd to assess the company's total reinvestment commitment from operating cash flow.
Mezzion Pharma Co.Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Mezzion Pharma Co.Ltd's total assets have evolved over time, based on quarterly financial data. Explore Mezzion Pharma Co.Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Mezzion Pharma Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Mezzion Pharma Co.Ltd's total assets of ₩98.92 Billion consist of 46.5% current assets and 53.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 26.1% |
| Accounts Receivable | ₩1.08 Billion | 1.1% |
| Inventory | ₩5.30 Billion | 5.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩49.12 Billion | 50.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Mezzion Pharma Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mezzion Pharma Co.Ltd (140410) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mezzion Pharma Co.Ltd's current assets represent 46.5% of total assets in 2025, a decrease from 88.5% in 2012.
- Cash Position: Cash and equivalents constituted 26.1% of total assets in 2025, down from 29.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 50.1% of total assets.
Mezzion Pharma Co.Ltd Competitors by Total Assets
Key competitors of Mezzion Pharma Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩222.34 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩642.14 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩324.89 Billion |
Mezzion Pharma Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.47 | 1.33 | 3.07 |
| Quick Ratio | 0.40 | 1.12 | 2.43 |
| Cash Ratio | 0.00 | 0.61 | 1.38 |
| Working Capital | ₩-43.95 Billion | ₩8.64 Billion | ₩37.26 Billion |
Mezzion Pharma Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Mezzion Pharma Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 126.26 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 32.5% |
| Total Assets | ₩98.02 Billion |
| Market Capitalization | $371.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mezzion Pharma Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Mezzion Pharma Co.Ltd's assets grew by 32.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mezzion Pharma Co.Ltd (2012–2025)
The table below shows the annual total assets of Mezzion Pharma Co.Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩98.02 Billion ≈ $66.43 Million |
+32.47% |
| 2024-12-31 | ₩74.00 Billion ≈ $50.15 Million |
-19.70% |
| 2023-12-31 | ₩92.15 Billion ≈ $62.45 Million |
+70.58% |
| 2022-12-31 | ₩54.02 Billion ≈ $36.61 Million |
-35.64% |
| 2021-12-31 | ₩83.93 Billion ≈ $56.88 Million |
+10.99% |
| 2020-12-31 | ₩75.63 Billion ≈ $51.25 Million |
+28.45% |
| 2019-12-31 | ₩58.87 Billion ≈ $39.90 Million |
-21.56% |
| 2018-12-31 | ₩75.06 Billion ≈ $50.87 Million |
+1.38% |
| 2017-12-31 | ₩74.04 Billion ≈ $50.17 Million |
-22.80% |
| 2016-12-31 | ₩95.90 Billion ≈ $64.99 Million |
-6.94% |
| 2015-12-31 | ₩103.05 Billion ≈ $69.84 Million |
+53.12% |
| 2012-12-31 | ₩67.30 Billion ≈ $45.61 Million |
-- |
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more